<DOC>
	<DOCNO>NCT01507064</DOCNO>
	<brief_summary>The purpose study determine whether neoadiuvant therapy sorafenib increase efficacy thermal ablation induce necrosis hepatocellular carcinoma .</brief_summary>
	<brief_title>Neoadjuvant Sorafenib Therapy Prior Laser Ablation Hepatocellular Carcinoma</brief_title>
	<detailed_description>BACKGROUND AND AIM Image-guided laser ablation ( LA ) , minimally invasive procedure , potentially viable treatment option achieve focal thermal destruction hepatocellular carcinoma ( HCC ) treat surgery . Both technique effective destruction small ( &lt; 3 cm ) tumor , success rate index tumor large 4 cm diameter lower . A cause difficulty treat large tumor represent heat-sink effect tumor blood flow limit size tumor ablation draw heat away tumor nodule . Surgical ( Pringle maneuver ) endovascular ( transarterial chemoembolization ) technique use reduce tumor blood flow thermal ablation , technique require invasive procedure may decrease patient acceptance increase risk complication . Sorafenib multikinase inhibitor approve treatment advance HCC . One main effect drug block vascular endothelial growth factor ( VEGF ) pathway , Flt-3 , c-KIT , fibroblast growth factor receptor 1 , show mediate tumor angiogenesis , reduce intratumoral blood flow . An experimental study mouse renal cell carcinoma implant subcutaneously , show treatment sorafenib ablation result markedly decreased cancer microvessel density significantly large zone radiofrequency-induced coagulation necrosis ( 1 ) . The purpose study determine sorafenib improve effectiveness laser ablation ( LA ) treatment HCC large 4cm size . 1 . Hakim√© A , Hines-Peralta A , Peddi H , Atkins MB , Sukhatme VP , Signoretti S , Regan M , Goldberg SN . Combination Radiofrequency Ablation Antiangiogenic Therapy Tumor Ablation Efficacy : Study Mice . Radiology 2007 , 244 , 464-470 . STUDY DESIGN Participants randomize receive either sorafenib ( 400mg twice day ) placebo continuously 4 week ( day 1-28 ) . LA perform day 29 . On day 0 28 , 1 , 6 , 12 month LA , patient undergo physical exam . Adverse event record use pre-planned questionnaire accordance `` common toxicity criterion '' . Occurrence characteristic postablation syndrome also record . During six-month period , clinically indicate LA procedure precede four-week sorafenib treatment , may repeat three time . Laboratory value assess day 0 28 , 1 , 6 , 12 month first LA procedure . Upper gastrointestinal endoscopy do start drug treatment . A tumor biopsy obtain time first LA . A CT MRI scan perform time inclusion study , 1 , 6 , 12 month LA .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age 1880 year ECOG = 0 1 No liver decompensation ( ChildPugh &lt; 8 ) , bilirubin &lt; 3mg/dL Patients unresectable HCC refuse surgery Confirmed HCC pathology AASLD image guideline At least one HCC nodule ( index tumor ) accurately measure 48cm diameter baseline image No prior therapy index tumor No prior systemic treatment HCC within 4 week study entry LA clinically indicate index tumor Hemoglobin &gt; 9.0 g/dl ; Platelet count correctable &gt; 50,000/mm3 ; INR correctable &lt; 2.0 . Other severe concomitant disease may reduce life expectancy Participants currently receive study agent Cancer vascular invasion extrahepatic metastasis Uncontrolled hypertension Thrombotic event myocardial infarction within past 6 month Hemorrhage/bleeding event within 4 week Evidence severe uncorrectable bleed diathesis coagulopathy Contraindication inability undergo LA procedure Human immunodeficiency virus ( HIV ) infection Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result Any condition unstable could jeopardize safety patient his/her compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>sorafenib</keyword>
	<keyword>laser ablation</keyword>
</DOC>